Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Investigational topical small molecule

PP405 — evidence

What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.

Evidence overview

1 record in this file

  • CLINICAL TRIAL1

Research areas. Investigational hair-follicle research.

Publication span. 2024.

What we know

    Editorial reading of the records below, labelled as Therapept analysis. How records are built

    What remains uncertain

      Regulatory notes

      Investigational

      • No approved United States product in Drugs@FDA as of this review.
      • Phase 2a trial NCT06393452 (PP405-2001) is registered as completed; the registry record describes a randomised, vehicle-controlled study with an open-label extension.
      • Phase 2 trial NCT07907783 in adult females with androgenetic alopecia was registered in 2026 with a not-yet-recruiting status at review.
      • Therapept has not indexed a peer-reviewed primary publication of the Phase 2a results. Sponsor presentations and press releases are not a substitute for a published trial report or an approval.

      Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.

      Studies and documents

      1. CLINICAL TRIAL2024Phase 2a randomised, vehicle-controlled trial with open-label extension (registry record)

        Safety, pharmacokinetics and efficacy of PP405 in adults with androgenetic alopecia (PP405-2001)

        Pelage Pharmaceuticals, Inc.ClinicalTrials.gov

        Population
        Adults with androgenetic alopecia
        Objective
        To assess the safety, pharmacokinetics and efficacy of topical PP405 in adults with androgenetic alopecia.
        Endpoint investigated
        Safety and pharmacokinetics, with efficacy measures, over blinded treatment and an open-label extension

        Study design

        Registry
        NCT06393452

        This describes the published study design. It is not a usage or dosing recommendation.

        The registry record describes a two-part Phase 2a study: a randomised, vehicle-controlled blinded period followed by a three-month open-label extension. The record's overall status is listed as completed.

        Limitations. This is a registry record, not a published trial report. Completion does not establish efficacy or safety, and Therapept has not indexed a peer-reviewed primary publication of the results.

        ClinicalTrials.gov — NCT06393452Reviewed 13 November 2026

      Last reviewed 13 November 2026 · Compiled by Therapept Editorial · How these records are built